Viking Therapeutics has completed patient enrolment in its Phase III VANQUISH-2 trial of VK2735, being developed in oral and subcutaneous formulations to potentially treat metabolic disorders such as obesity.
VK2735 is the company’s dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The double-blind, randomised, placebo-controlled, multi-centre study focuses on adults who have type 2 diabetes (T2D) and obesity or are overweight, evaluating subcutaneous VK2735 for potential obesity treatment.
It enrolled around 1,000 adults with T2D and a body mass index (BMI) of at least 30kg/m² or who are overweight with a BMI of at least 27kg/m².
Patients were randomised to receive one of four weekly treatment arms: VK2735 at 7.5mg, 12.5mg, 17.5mg, or placebo, administered for 78 weeks.
The primary endpoint measures percent change in body weight from baseline after 78 weeks compared to placebo.
Secondary and exploratory endpoints include the proportion of patients achieving at least 5%, 10%, 15% and 20% body weight reduction. A 52-week extension period allows ongoing treatment following the main dosing phase.
Viking Therapeutics CEO Brian Lian said: “Completing enrolment in the VANQUISH-2 study is an important milestone for Viking as it is the second of our two registration studies to be fully enrolled.
“As with the VANQUISH-1 study, we are happy to see a study of this size enrol quickly, which we believe speaks to the enthusiasm for new obesity treatments beyond those currently available. We look forward to completing the VANQUISH studies in 2027.”
Alongside VANQUISH-2, Viking is conducting the Phase III VANQUISH-1 trial of VK2735 in patients who have obesity or are overweight.
In November 2025, Viking Therapeutics concluded participant enrolment in the Phase III VANQUISH-1 trial of subcutaneous VK2735.
